288 related articles for article (PubMed ID: 15183783)
1. Survival after proton-beam irradiation of uveal melanomas.
Kodjikian L; Roy P; Rouberol F; Garweg JG; Chauvel P; Manon L; Jean-Louis B; Little RE; Sasco AJ; Grange JD
Am J Ophthalmol; 2004 Jun; 137(6):1002-10. PubMed ID: 15183783
[TBL] [Abstract][Full Text] [Related]
2. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).
Dendale R; Lumbroso-Le Rouic L; Noel G; Feuvret L; Levy C; Delacroix S; Meyer A; Nauraye C; Mazal A; Mammar H; Garcia P; D'Hermies F; Frau E; Plancher C; Asselain B; Schlienger P; Mazeron JJ; Desjardins L
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):780-7. PubMed ID: 16647221
[TBL] [Abstract][Full Text] [Related]
3. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience.
Caujolle JP; Mammar H; Chamorey E; Pinon F; Herault J; Gastaud P
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):98-103. PubMed ID: 19910136
[TBL] [Abstract][Full Text] [Related]
4. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):517-25. PubMed ID: 15453846
[TBL] [Abstract][Full Text] [Related]
6. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas.
Puusaari I; Heikkonen J; Summanen P; Tarkkanen A; Kivelä T
Ophthalmology; 2003 Nov; 110(11):2223-34. PubMed ID: 14597534
[TBL] [Abstract][Full Text] [Related]
7. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences.
Caujolle JP; Paoli V; Chamorey E; Maschi C; Baillif S; Herault J; Gastaud P; Hannoun-Levi JM
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1218-24. PubMed ID: 23177670
[TBL] [Abstract][Full Text] [Related]
8. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.
Gragoudas ES; Lane AM; Munzenrider J; Egan KM; Li W
Trans Am Ophthalmol Soc; 2002; 100():43-8; discussion 48-9. PubMed ID: 12545676
[TBL] [Abstract][Full Text] [Related]
9. No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma.
Furdova A; Slezak P; Chorvath M; Waczulikova I; Sramka M; Kralik G
Neoplasma; 2010; 57(4):377-81. PubMed ID: 20429631
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up after uveal melanoma charged particle therapy.
Char DH; Kroll SM; Castro J
Trans Am Ophthalmol Soc; 1997; 95():171-87; discussion 187-91. PubMed ID: 9440169
[TBL] [Abstract][Full Text] [Related]
12. A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma.
Kroll S; Char DH; Quivey J; Castro J
Ophthalmology; 1998 Nov; 105(11):2035-45. PubMed ID: 9818602
[TBL] [Abstract][Full Text] [Related]
13. Posterior uveal melanoma in young patients treated with proton beam therapy.
Vavvas D; Kim I; Lane AM; Chaglassian A; Mukai S; Gragoudas E
Retina; 2010 Sep; 30(8):1267-71. PubMed ID: 20224468
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetics of uveal melanoma: a 7-year clinical experience.
Damato B; Duke C; Coupland SE; Hiscott P; Smith PA; Campbell I; Douglas A; Howard P
Ophthalmology; 2007 Oct; 114(10):1925-31. PubMed ID: 17719643
[TBL] [Abstract][Full Text] [Related]
15. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation.
Marucci L; Ancukiewicz M; Lane AM; Collier JM; Gragoudas ES; Munzenrider JE
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):842-6. PubMed ID: 20472356
[TBL] [Abstract][Full Text] [Related]
16. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability.
Coupland SE; Campbell I; Damato B
Ophthalmology; 2008 Oct; 115(10):1778-85. PubMed ID: 18554722
[TBL] [Abstract][Full Text] [Related]
17. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
18. Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma.
Marucci L; Lane AM; Li W; Egan KM; Gragoudas ES; Adams JA; Collier JM; Munzenrider JE
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1018-22. PubMed ID: 16376492
[TBL] [Abstract][Full Text] [Related]
19. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
[TBL] [Abstract][Full Text] [Related]
20. Metastatic melanoma in the eye and orbit.
Zografos L; Ducrey N; Beati D; Schalenbourg A; Spahn B; Balmer A; Othenin-Girard CB; Chamot L; Egger E
Ophthalmology; 2003 Nov; 110(11):2245-56. PubMed ID: 14597536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]